Page 39 - Read Online

Oquendo et al. J Transl Genet Genom 2021;5:89-111 https://dx.doi.org/10.20517/jtgg.2021.04 Page 111

lymphoma: initial results of the MAGNOLIA (BGB-3111-214) trial. Blood 2020;136:28-30. DOI
116. Zinzani P, Samaniego F, Jurczak W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with
relapsed/refractory marginal zone lymphoma: a multicenter, open-label, registration directed phase 2 study. Hematol Oncol
2019;37:182-3.
117. Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-
up and biomarker analysis. Blood Adv 2020;4:5773-84. DOI PubMed PMC
118. Panayiotidis P, Follows GA, Mollica L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone
lymphoma. Blood Adv 2021;5:823-8. DOI PubMed PMC
119. Tarantelli C, Lange M, Gaudio E, et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and
T-cell lymphoma models. Blood Adv 2020;4:819-29. DOI PubMed PMC
120. Arribas AJ, Napoli S, Cascione L, et al. Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone
lymphoma. Blood Cancer Discovery 2020. DOI
121. Andrade-campos MM, Salar A, Sanchez-gonzalez B, et al. Assessment of cell-free DNA (cfDNA) in 221 patients with
lymphoproliferative malignancies at diagnosis and during follow-up. Blood 2019;134:492. DOI
122. Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 2017;129:1947-57.
DOI PubMed
123. Zhou W, Dinh HQ, Ramjan Z, et al. DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat Genet
2018;50:591-602. DOI PubMed PMC
124. Le Bris Y, Struski S, Guièze R, et al. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status
in first-line chronic lymphocytic leukemia. Hematol Oncol 2017;35:664-70. DOI PubMed
125. Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in
relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015;121:3612-21. DOI
PubMed PMC
126. Greenwell IB, Staton AD, Lee MJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and
poor response to intensive induction therapy. Cancer 2018;124:2306-15. DOI PubMed PMC
127. Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor
venetoclax. Blood 2017;129:3362-70. DOI PubMed
128. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE
study in patients with previously treated CLL/SLL. Leukemia 2018;32:83-91. DOI PubMed PMC
129. Gisselsson D, Pettersson L, Höglund M, et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity.
Proc Natl Acad Sci U S A 2000;97:5357-62. DOI PubMed PMC
130. Barthel FP, Wei W, Tang M, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet
2017;49:349-57. DOI PubMed PMC
131. Rampazzo E, Bonaldi L, Trentin L, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic
leukemia with different biological characteristics and clinical outcomes. Haematologica 2012;97:56-63. DOI PubMed PMC
132. Strefford JC, Kadalayil L, Forster J, et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia:
data from the UK LRF CLL4 trial. Leukemia 2015;29:2411-4. DOI PubMed PMC
133. Parker AE, Snell K, Davis Z, Oscier DG. Telomere length by Tel-PCR in B cell malignancies. Blood 2005;106:2955. DOI
134. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47. DOI PubMed PMC
135. Baird DM, Rowson J, Wynford-Thomas D, Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells.
Nat Genet 2003;33:203-7. DOI PubMed
136. Lai TP, Zhang N, Noh J, et al. A method for measuring the distribution of the shortest telomeres in cells and tissues. Nat Commun
2017;8:1356. DOI PubMed PMC
137. Kahl VFS, Allen JAM, Nelson CB, et al. Telomere Length Measurement by Molecular Combing. Front Cell Dev Biol 2020;8:493.
DOI PubMed PMC
138. Bruscaggin A, Mollejo M, Tapia G, et al. Multi-omics landscape of splenic marginal zone lymphoma (SMZL) - interim analysis of
IELSG46 study. Hematol Oncol 2019;37:181-2. DOI
139. Guidetti F, Bruscaggin A, Frigeni M, et al. Molecular subtypes of splenic marginal zone lymphoma (SMZL) are associated with
distinct pathogenic mechanisms and outcomes - interim analysis of the IELSG46 study. Blood 2018;132:922. DOI